Why the study?
Does dual therapy with dabigatran and a P2Y12 inhibitor reduce the risk of bleeding in patients with atrial fibrillation who had undergone PCI?
Does dual therapy with dabigatran and a P2Y12 inhibitor reduce the risk of bleeding in patients with atrial fibrillation who had undergone PCI?
In patients with atrial fibrillation undergoing PCI, dual antithrombotic therapy with dabigatran reduces bleeding risk compared to triple therapy with warfarin, without compromising protection against thromboembolic events.
Answers are grounded in this paper and cite their sources.
Supports dual dabigatran therapy post-PCI in AF to reduce bleeding; confirms noninferior thromboembolic protection versus triple therapy.
Among patients with atrial fibrillation who had undergone PCI, the risk of bleeding was lower among those who received dual therapy with dabigatran and a P2Y₁₂ inhibitor than among those who received triple therapy with warfarin, a P2Y₁₂ inhibitor, and aspirin. Dual therapy was noninferior to triple therapy with respect to the risk of thromboembolic events. (Funded by Boehringer Ingelheim; RE-DUAL PCI ClinicalTrials.gov number, NCT02164864 .).
No takes yet. Share an insight, caveat, or question.
Cannon et al. (2017) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: